Shogo Kotsuka
Directeur/Membre du Conseil chez Biomedica Solution KK
Profil
Shogo Kotsuka is currently a Director at Biomedica Solution KK since 2014.
Prior to this, he worked as a Director & GM-Business Planning Administration at tella, Inc. from 2016 to 2017 and as a Director at Titan, Inc. (Japan).
Postes actifs de Shogo Kotsuka
| Sociétés | Poste | Début |
|---|---|---|
Biomedica Solution KK
 Biomedica Solution KK BiotechnologyHealth Technology Part of Tella, Inc., Biomedica Solution KK is a Japanese company that manufactures cell production facilities. | Directeur/Membre du Conseil | 01/02/2014 |
Anciens postes connus de Shogo Kotsuka
| Sociétés | Poste | Fin |
|---|---|---|
Titan, Inc. (Japan)
 Titan, Inc. (Japan) Data Processing ServicesTechnology Services Titan, Inc. provides imaging solutions and clinical trial support services. The company was founded on May 2, 2013 and is headquartered in Tokyo, Japan. | Directeur/Membre du Conseil | - |
| TELLA, INC. | Directeur Financier/CFO | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Titan, Inc. (Japan)
Titan, Inc. (Japan) Data Processing ServicesTechnology Services Titan, Inc. provides imaging solutions and clinical trial support services. The company was founded on May 2, 2013 and is headquartered in Tokyo, Japan. | Technology Services |
Biomedica Solution KK
Biomedica Solution KK BiotechnologyHealth Technology Part of Tella, Inc., Biomedica Solution KK is a Japanese company that manufactures cell production facilities. | Health Technology |
tella, Inc.
 tella, Inc. BiotechnologyHealth Technology tella, Inc. engages in research and development of dendritic cell (DC) vaccine therapy. It operates through the following segments: Cell Medicine, Medical Support, and Pharmaceuticals. The Cell Medicine segment provides cancer treatment technology and know-hows centered on dendritic cell vaccine therapy. The Medical Support segment manages contact research organization (CRO) business and offers genetic testing services. The Pharmaceuticals segment deals with the development of dendritic cell vaccine as a cancer treatment. The company was founded by Yuichiro Yazaki on June 24, 2004 and is headquartered in Tokyo, Japan. | Health Technology |
